Gavreto (pralsetinib) — Medica

Initial criteria

• Patient is age ≥ 12 years
• Patient has unresectable, recurrent, or metastatic disease
• The disease is positive for rearranged during transfection (RET) pathogenic variant
• Patient is continuing therapy with Gavreto

Approval duration

1 year